Plain-English translation of NCT06656949 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing the best way to use a fluorescent dye called indocyanine green (ICG) to help surgeons identify and remove sentinel lymph nodes—the first lymph nodes where cancer might spread—during endometrial cancer surgery. The trial compares injecting the dye in one location (the cervix) versus two locations (both the cervix and uterus) to see which approach works better. The goal is to avoid unnecessary removal of many lymph nodes while still catching any cancer that may have spread.
Most endometrial cancers are confined to the uterus, which means not every patient needs their lymph nodes removed. However, surgeons need a reliable way to identify which lymph nodes are at risk. This trial will show whether using the fluorescent dye in one or two locations is the most effective approach, potentially reducing surgery time and recovery complications.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive laparoscopic surgery for your endometrial cancer. Before surgery begins, surgeons will inject the fluorescent dye (indocyanine green) either into your cervix alone or into both your cervix and uterus, depending on which group you're assigned to. During surgery, they will use special imaging to identify the sentinel lymph nodes that light up from the dye, remove them, and examine them immediately. If cancer is found in these nodes, your surgeon will remove additional lymph nodes as part of standard treatment. The entire process is part of your cancer surgery, and you won't need additional visits specifically for the trial.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China